×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARCT – arcturus therapeutics holdings inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARCT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/23
03:08 pm
arct
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf [Yahoo! Finance]
3/23
07:34 am
arct
These Are the Only 3 Stocks That Cathie Wood Bought Last Week [Yahoo! Finance]
Medium
Report
These Are the Only 3 Stocks That Cathie Wood Bought Last Week [Yahoo! Finance]
3/20
08:07 am
arct
Arcturus Therapeutics (ARCT) was upgraded by B. Riley Financial, Inc. to "strong-buy".
Low
Report
Arcturus Therapeutics (ARCT) was upgraded by B. Riley Financial, Inc. to "strong-buy".
3/18
08:03 am
arct
Arcturus Therapeutics (ARCT) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $22.00 price target on the stock.
Low
Report
Arcturus Therapeutics (ARCT) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $22.00 price target on the stock.
3/12
02:17 am
arct
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing [Yahoo! Finance]
Medium
Report
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing [Yahoo! Finance]
3/6
04:08 pm
arct
Arcturus Therapeutics: Downgrading To "Hold" As CF Program Shifts Population Focus [Seeking Alpha]
Medium
Report
Arcturus Therapeutics: Downgrading To "Hold" As CF Program Shifts Population Focus [Seeking Alpha]
3/5
03:24 pm
arct
Arcturus Therapeutics (ARCT) had its price target lowered by Citigroup Inc. from $66.00 to $21.00. They now have a "buy" rating on the stock.
Neutral
Report
Arcturus Therapeutics (ARCT) had its price target lowered by Citigroup Inc. from $66.00 to $21.00. They now have a "buy" rating on the stock.
3/5
09:00 am
arct
Arcturus Therapeutics to Attend Upcoming Investor Conference
Medium
Report
Arcturus Therapeutics to Attend Upcoming Investor Conference
Date
Time
Symbol
Company Name
Action
%Chg
3/3/2026
04:01 pm
arct
arcturus therapeutics holdings inc.
MISS
Report
-4.7%
arcturus therapeutics holdings inc.
11/10/2025
04:01 pm
arct
arcturus therapeutics holdings inc.
BEAT
Report
-1.3%
arcturus therapeutics holdings inc.
8/11/2025
04:01 pm
arct
arcturus therapeutics holdings inc.
BEAT
Report
7.3%
arcturus therapeutics holdings inc.
5/12/2025
04:01 pm
arct
arcturus therapeutics holdings inc.
BEAT
Report
2.3%
arcturus therapeutics holdings inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/3
04:39 pm
arct
Form 10-K Arcturus Therapeutics For: Dec 31
Low
Report
Form 10-K Arcturus Therapeutics For: Dec 31
3/3
04:08 pm
arct
Form 8-K Arcturus Therapeutics For: Mar 03
Medium
Report
Form 8-K Arcturus Therapeutics For: Mar 03
2/17
06:49 am
arct
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: BALYASNY ASSET MANAGEMENT L.P.
Medium
Report
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: BALYASNY ASSET MANAGEMENT L.P.
2/3
11:27 am
arct
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: ARK Investment Management LLC
Medium
Report
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: ARK Investment Management LLC
1/8
08:13 am
arct
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: FEDERATED HERMES, INC.
Low
Report
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: FEDERATED HERMES, INC.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/27
Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
29.7%
3/15 Arcturus Therapeutics Holdings Inc. Analysts Are Pretty Bullish On The Stock After Recent Results [Yahoo! Finance News] 22.1%
3/23 Form SEC STAFF LETTER Arcturus Therapeutics 19.3%
3/4 Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™ 15.7%
8/15 Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 14.3%
3/5 Arcturus Therapeutics Ltd (NASDAQ: ARCT) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating. 14.1%
7/30 Form EFFECT Arcturus Therapeutics 12.5%
6/20 Form 8-K Arcturus Therapeutics For: Jun 18 Filed by: Arcturus Therapeutics Holdings Inc. 12.3%
9/23 Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors 11.9%
6/20 Arcturus Therapeutics Ltd (NASDAQ: ARCT) was given a new $18.00 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. 11.3%
3/15 Arcturus Therapeutics Holdings Inc. Analysts Are Pretty Bullish On The Stock After Recent Results [Yahoo! Finance News] 22.1%
3/23 Form SEC STAFF LETTER Arcturus Therapeutics 19.3%
3/4 Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™ 15.7%
8/15 Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 14.3%
3/5 Arcturus Therapeutics Ltd (NASDAQ: ARCT) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating. 14.1%
7/30 Form EFFECT Arcturus Therapeutics 12.5%
6/20 Form 8-K Arcturus Therapeutics For: Jun 18 Filed by: Arcturus Therapeutics Holdings Inc. 12.3%
9/23 Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors 11.9%
6/20 Arcturus Therapeutics Ltd (NASDAQ: ARCT) was given a new $18.00 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. 11.3%
TOP News Decliners
3/12
Arcturus Therapeutics Holdings, Inc. (ARCT) CEO Joseph Payne on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-29.3%
4/28 Thinking about trading stocks or options in Arcturus Therapeutics, Laboratory Corp. of America, Bed Bath & Beyond, Moderna, or Zillow? -13.4%
3/27 Form 8-K Arcturus Therapeutics For: Mar 27 -13.2%
5/10 Q1/2019 3/31/2019 EPS -0.680 ZacksConsensus N/A ActVsEst N/A - N/A -13.2%
8/5 Form 424B5 Arcturus Therapeutics -12.9%
8/1 Form 8-K Arcturus Therapeutics For: Aug 01 -12.1%
8/15 Q2/2019 6/30/2019 EPS -0.070 ZacksConsensus -0.530 ActVsEst 0.460 - Beat -11.9%
9/26 Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock -9.8%
3/19 Arcturus Therapeutics Ltd (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $26.00 price target on the stock. -8.4%
2/24 Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11 -8.1%
4/28 Thinking about trading stocks or options in Arcturus Therapeutics, Laboratory Corp. of America, Bed Bath & Beyond, Moderna, or Zillow? -13.4%
3/27 Form 8-K Arcturus Therapeutics For: Mar 27 -13.2%
5/10 Q1/2019 3/31/2019 EPS -0.680 ZacksConsensus N/A ActVsEst N/A - N/A -13.2%
8/5 Form 424B5 Arcturus Therapeutics -12.9%
8/1 Form 8-K Arcturus Therapeutics For: Aug 01 -12.1%
8/15 Q2/2019 6/30/2019 EPS -0.070 ZacksConsensus -0.530 ActVsEst 0.460 - Beat -11.9%
9/26 Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock -9.8%
3/19 Arcturus Therapeutics Ltd (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $26.00 price target on the stock. -8.4%
2/24 Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11 -8.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: